Norden Group LLC Buys New Shares in iShares Biotechnology ETF $IBB

Norden Group LLC purchased a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 42,459 shares of the financial services provider’s stock, valued at approximately $7,166,000. Norden Group LLC owned about 0.08% of iShares Biotechnology ETF as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of IBB. BNP Paribas Financial Markets grew its stake in shares of iShares Biotechnology ETF by 313.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,915,395 shares of the financial services provider’s stock valued at $276,526,000 after buying an additional 1,451,820 shares during the period. JPMorgan Chase & Co. raised its position in shares of iShares Biotechnology ETF by 27.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,060,048 shares of the financial services provider’s stock worth $153,039,000 after buying an additional 226,852 shares during the period. Jefferies Financial Group Inc. purchased a new position in shares of iShares Biotechnology ETF in the 3rd quarter worth $65,083,000. Barclays PLC boosted its holdings in iShares Biotechnology ETF by 6.7% in the third quarter. Barclays PLC now owns 416,191 shares of the financial services provider’s stock valued at $60,085,000 after acquiring an additional 26,032 shares during the last quarter. Finally, Focus Partners Wealth boosted its holdings in iShares Biotechnology ETF by 8.8% in the third quarter. Focus Partners Wealth now owns 116,844 shares of the financial services provider’s stock valued at $16,878,000 after acquiring an additional 9,404 shares during the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

IBB stock opened at $165.38 on Friday. The stock has a 50-day moving average price of $171.36 and a two-hundred day moving average price of $163.94. iShares Biotechnology ETF has a 12-month low of $107.43 and a 12-month high of $179.64.

iShares Biotechnology ETF Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 20th. Stockholders of record on Tuesday, March 17th were paid a $0.1218 dividend. This represents a $0.49 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend was Tuesday, March 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.